自兴人工智能：AI突破血液肿瘤精准诊断

Abstract:In recent years，with the development of Biomedicine，novel and precision targeted therapies for tumors represented by “Chimeric Antigen Receptor T-Cell （CAR-T） Immunotherapy” have been widely used in the clinical treatment of hematological tumors to achieve complete cure of leukemia. Yet the prerequisite of precision diagnosis and treatment is the precise typing，including comprehensive analysis of Morpho-cytology，Immunology，Cytogenetics and Molecular Biology （MICM）. Especially，Cytogenetics analysis，namely Karyotyping，is of critical importance in clinical diagnosis and prognosis of hematological cancers. However，the current situation of the Karyotyping industry in domestic is quite unfavorable：lack of chromosome samples，large sample diversity，many difficulties in sample preparation，high reliance on foreign countries-imported scanning and diagnostic equipment，and so forth. To breakthrough these bottlenecks，Zixing AI has dedicated and successfully developed a comprehensive solution that integrates scanning，patting，analysis and reporting functions. This solution has been proved to be effective in breaking through the bottlenecks of the industry，including high reliance on manual labor，many difficulties to accumulate expertise，lack of skilled workers as well as too much reliance on foreign countries-imported equipment for chromosome karyotyping. These achievements have remarkably promoted the progress of chromosome karyotyping industry.

收起